Chris Obrien Lifehouse

Futó vizsgálatok

• Még nem toboroz

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· 1/2. fázis· Forrás

• Toboroz

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· 1/2. fázis· Forrás

• Toboroz

  Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  NCT07493512· 1. fázis· Forrás

• Toboroz

  Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  NCT07297979· 1. fázis· Forrás

• Toboroz

  A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07244341· 1. fázis· Forrás

• Toboroz

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· 1. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· 3. fázis· Forrás

• Toboroz

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· 1. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· 3. fázis· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Forrás

• Toboroz

  Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

  NCT06598306· 1. fázis· Forrás

• Fut, nem toboroz

  Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

  NCT06555796· 1. fázis· Forrás

• Toboroz

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· 3. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· 1. fázis· Forrás

• Toboroz

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· 1. fázis· Forrás

• Fut, nem toboroz

  First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  NCT05361395· 1. fázis· Forrás

• Fut, nem toboroz

  Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

  NCT05215340· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

  NCT05094336· 1/2. fázis· Forrás

• Toboroz

  Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· 1. fázis· Forrás

• Fut, nem toboroz

  Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

  NCT03319940· 1. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák5 toboroz
• Prosztatarák4 toboroz
• Vastagbélrák3 toboroz
• Hasnyálmirigyrák2 toboroz
• Gyermekkori daganatok1 toboroz
• Neuroendokrin daganatok1 toboroz
• Szarkóma1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT05635708· 2. fázis· Forrás

• Lezárult

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· 3. fázis· Forrás

• Lezárult

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· 1. fázis· Forrás

• Lezárult

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· 1. fázis· Forrás

• Lezárult

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· 3. fázis· Forrás

• Lezárult

  Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

  NCT03358472· 3. fázis· Forrás